NCT06831175View on ClinicalTrials.gov

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2031

Conditions
Adrenal Cortical CarcinomaAdrenal Cortical CancerAdrenal Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab was administered 200mg IV every 3 weeks.

DRUG

Apatinib

Apatinib was administered 250 mg PO QD.

DRUG

mitotane

Mitotane is administered orally and plasma concentration was measured. The target steady-state plasma concentration is 14-20 mg/L.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER